GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Construction In Progress

Accelerated Pharma (Accelerated Pharma) Construction In Progress : $0.00 Mil (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Construction In Progress?

Accelerated Pharma Construction In Progress Historical Data

The historical data trend for Accelerated Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Construction In Progress Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Construction In Progress
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Construction In Progress Get a 7-Day Free Trial - - - - -

Accelerated Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Construction In Progress
Comparable Companies
NUVPF ADMD RSPI YBAO ULUR NRXCF ACUR LBLTF PUFXF BKIT RLMD IGC MYOS CBICF SBFM PVCT AQSZF PTLF AOLS APRI
Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines